Key Inclusion Criteria:  Dose escalation: subjects with RRMM who have progressed on, or could not tolerate, all available established therapies and subjects with recurrent and refractory lymphoma. Dose expansion_cohort 1: subjects with RRMM who have progressed on, or could not tolerate, all available established therapies. Dose expansion_cohort 2: subjects with RRMM who have progressed on, or could not tolerate, all available established therapies, or subjects with NDMM. For MM: Documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria. For MM: Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 0.5 gram per deciliter (g/dL) or urine M-protein level >=200 milligram per 24 hours (mg/24 h) or light chain multiple myeloma without measurable disease in the serum or the urine: serum immunoglobulin free light chain (FLC) >= 10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio. Eastern Cooperative Oncology Group (ECOG) performance status score <＝2. Women of childbearing potential and male subjects must agree to remain abstinent or use contraceptive methods as defined by the protocol. Side effects of any prior therapy or procedures for any medical condition has recovered to NCI-CTCAE v.5.0 Grade ≤ 1.  Key Exclusion Criteria:  Previous treatment with any anti-CD38 therapy. Subjects with concurrent plasma cell leukemia. Received a cumulative dose of corticosteroids equivalent to greater than or equal to ( >=) 140 milligram (mg) of prednisone within the 14-day period before the first dose of study drug (does not include pretreatment medication). Vaccinated with live, attenuated vaccine within 4 weeks prior to the first dose. Received an allogenic stem cell transplant or an autologous stem cell transplant within 3 months before first dose of study drug. Central nervous system (CNS) involvement. The forced expiratory volume in one second (FEV1)<60%.